BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

As Werewolf moves toward the clinic with two lead oncology candidates and a $72 million crossover round, the company’s conditionally-activated immune modulation platform is also provoking interest from potential partners. The Cambridge, Mass.-based biotech closed...
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million in a series A round led by Rock Springs Capital; T. Rowe Price Associates, Andreessen Horowitz, Menlo Ventures, Radical Ventures,...
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

...$5.4M A roundBiodol Therapeutics received €4.5 million ($5.4 million) in series A financing led by V-Bio Ventures...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...Mummenbrauer expects the series A round -- which saw participation from VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures...
...of employees: 3 Funds raised: €23 million ($26.9 million) Investors: Fund+, VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures...
...von Willebrand factor Danielle Golovin, Staff Writer Cablivi, anti-vWF Nanobody, caplacizumab (ALX-0081/ALX-0681) Flanders Institute for Biotechnology (VIB) UCB Ventures SFPI-FPIM V-Bio Ventures Fund+ Ghent...
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros’ $56 million series C round early this month appears to be the last stepping stone towards an IPO intended to fund its ongoing clinical work. Despite the volatile public markets, the hematological and musculoskeletal...
BioCentury | Mar 12, 2020
Finance

March 11 Quick Takes: PDL, Kala, InnoCare, LifeSci, BioSight, BillionToOne, SEC

PDL to dissolve by year-end PDL BioPharma Inc. (NASDAQ:PDLI) said it will cease operations and seek to sell the company or monetize its assets. PDL acquires commercial-stage pharmaceutical assets and late clinical stage products. On...
BioCentury | Mar 11, 2020
Finance

Arkin ramping up investments with $140M fund

Arkin Holdings closed its second biopharma fund Monday at $140 million, more than double its debut fund, which launched with $60 million in 2016 and was fully committed at the end of 2019. As with...
BioCentury | Jan 10, 2020
Company News

Boehringer continues fibrosis drive via acquisition of Enleofen assets

The acquisition of Enleofen’s preclinical IL-11 inhibition platform is the latest in a string of deals by Boehringer to build out its fibrosis tool kit, giving the German pharma therapies against a new target for...
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

Future Ventures leads Deep Genomics’ $40M series B Looking to submit INDs for two programs this year, Deep Genomics Inc. raised $40 million in a series B round led by Future Ventures, with participation from...
Items per page:
1 - 10 of 100
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

As Werewolf moves toward the clinic with two lead oncology candidates and a $72 million crossover round, the company’s conditionally-activated immune modulation platform is also provoking interest from potential partners. The Cambridge, Mass.-based biotech closed...
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million in a series A round led by Rock Springs Capital; T. Rowe Price Associates, Andreessen Horowitz, Menlo Ventures, Radical Ventures,...
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

...$5.4M A roundBiodol Therapeutics received €4.5 million ($5.4 million) in series A financing led by V-Bio Ventures...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...Mummenbrauer expects the series A round -- which saw participation from VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures...
...of employees: 3 Funds raised: €23 million ($26.9 million) Investors: Fund+, VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures...
...von Willebrand factor Danielle Golovin, Staff Writer Cablivi, anti-vWF Nanobody, caplacizumab (ALX-0081/ALX-0681) Flanders Institute for Biotechnology (VIB) UCB Ventures SFPI-FPIM V-Bio Ventures Fund+ Ghent...
BioCentury | Mar 27, 2020
Emerging Company Profile

Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability. 4Bio Capital and Arkin Bio Ventures led the tranched round....
BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros’ $56 million series C round early this month appears to be the last stepping stone towards an IPO intended to fund its ongoing clinical work. Despite the volatile public markets, the hematological and musculoskeletal...
BioCentury | Mar 12, 2020
Finance

March 11 Quick Takes: PDL, Kala, InnoCare, LifeSci, BioSight, BillionToOne, SEC

PDL to dissolve by year-end PDL BioPharma Inc. (NASDAQ:PDLI) said it will cease operations and seek to sell the company or monetize its assets. PDL acquires commercial-stage pharmaceutical assets and late clinical stage products. On...
BioCentury | Mar 11, 2020
Finance

Arkin ramping up investments with $140M fund

Arkin Holdings closed its second biopharma fund Monday at $140 million, more than double its debut fund, which launched with $60 million in 2016 and was fully committed at the end of 2019. As with...
BioCentury | Jan 10, 2020
Company News

Boehringer continues fibrosis drive via acquisition of Enleofen assets

The acquisition of Enleofen’s preclinical IL-11 inhibition platform is the latest in a string of deals by Boehringer to build out its fibrosis tool kit, giving the German pharma therapies against a new target for...
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

Future Ventures leads Deep Genomics’ $40M series B Looking to submit INDs for two programs this year, Deep Genomics Inc. raised $40 million in a series B round led by Future Ventures, with participation from...
Items per page:
1 - 10 of 100